Lyndsay V Rhodes

Summary

Affiliation: Tulane University
Country: USA

Publications

  1. pmc Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells
    Lyndsay V Rhodes
    Department of Medicine, Tulane University Health Sciences Center, 1430 Tulane Ave, New Orleans, LA 70112, USA
    Exp Cell Res 317:2573-81. 2011
  2. pmc Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk
    Lyndsay V Rhodes
    Department of Medicine, Section of Haematology and Medical Oncology, Tulane University Health Science Centre, New Orleans, Louisiana, USA
    Mol Cancer 9:295. 2010
  3. pmc MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis
    James W Antoon
    Department of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana, USA
    PLoS ONE 8:e69291. 2013
  4. pmc Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition
    James W Antoon
    Department of Medicine, Section of Hematology and Medical Oncology, Tulane University School of Medicine, New Orleans, LA 70112, USA
    Int J Oncol 42:1139-50. 2013
  5. pmc Insulin-like growth factor-1 signaling regulates miRNA expression in MCF-7 breast cancer cell line
    Elizabeth C Martin
    Department of Medicine Section of Hematology and Medical Oncology, Tulane University, New Orleans, LA, USA
    PLoS ONE 7:e49067. 2012
  6. pmc Endocrine disruptor regulation of microRNA expression in breast carcinoma cells
    Syreeta L Tilghman
    Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, Louisiana, United States of America
    PLoS ONE 7:e32754. 2012
  7. ncbi request reprint Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer
    James W Antoon
    Tulane Department of Pharmacology Section of Hematology and Medical Oncology, Tulane Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, SL 83, New Orleans, Louisiana 70112, USA
    J Mol Endocrinol 46:205-16. 2011
  8. pmc Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
    Chandra R Tate
    Department of Medicine, Section of Hematology and Medical Oncology, Tulane University Health Sciences Center, 1430 Tulane Ave, New Orleans, LA 70112, USA
    Breast Cancer Res 14:R79. 2012
  9. pmc Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance
    James W Antoon
    Departments of Pharmacology, Tulane University School of Medicine, Tulane Avenue, New Orleans, LA, USA
    Sci Rep 2:539. 2012
  10. pmc Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells
    Quan Jiang
    Department of Chemistry, Xavier University of Louisiana, New Orleans, Louisiana 70125, USA
    J Med Chem 53:6153-63. 2010

Collaborators

Detail Information

Publications20

  1. pmc Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells
    Lyndsay V Rhodes
    Department of Medicine, Tulane University Health Sciences Center, 1430 Tulane Ave, New Orleans, LA 70112, USA
    Exp Cell Res 317:2573-81. 2011
    ..These findings represent future potential therapeutic targets for the treatment of hormone-independent and endocrine-resistant breast cancer...
  2. pmc Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk
    Lyndsay V Rhodes
    Department of Medicine, Section of Haematology and Medical Oncology, Tulane University Health Science Centre, New Orleans, Louisiana, USA
    Mol Cancer 9:295. 2010
    ..Therefore, we set out to investigate the impact of hMSCs on the oestrogen receptor positive, hormone-dependent breast carcinoma cell line MCF-7...
  3. pmc MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis
    James W Antoon
    Department of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana, USA
    PLoS ONE 8:e69291. 2013
    ..Given the need for new clinical therapeutic targets, our results demonstrate the therapeutic potential of targeting the MEK5-ERK5 pathway in breast cancer. ..
  4. pmc Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition
    James W Antoon
    Department of Medicine, Section of Hematology and Medical Oncology, Tulane University School of Medicine, New Orleans, LA 70112, USA
    Int J Oncol 42:1139-50. 2013
    ....
  5. pmc Insulin-like growth factor-1 signaling regulates miRNA expression in MCF-7 breast cancer cell line
    Elizabeth C Martin
    Department of Medicine Section of Hematology and Medical Oncology, Tulane University, New Orleans, LA, USA
    PLoS ONE 7:e49067. 2012
    ..Taken together, these data give new insights into mechanisms governing IGF-1 signaling in breast cancer...
  6. pmc Endocrine disruptor regulation of microRNA expression in breast carcinoma cells
    Syreeta L Tilghman
    Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, Louisiana, United States of America
    PLoS ONE 7:e32754. 2012
    ..Given the important implications of EDC-regulated ER function, we sought to define the effects of BPA and DDT on microRNA regulation and expression levels in estrogen-responsive human breast cancer cells...
  7. ncbi request reprint Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer
    James W Antoon
    Tulane Department of Pharmacology Section of Hematology and Medical Oncology, Tulane Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, SL 83, New Orleans, Louisiana 70112, USA
    J Mol Endocrinol 46:205-16. 2011
    ..This inhibitor binds the ER directly in the antagonist ligand-binding domain. Taken together, our results suggest that SKIs have the ability to act as novel ER signaling inhibitors in breast carcinoma...
  8. pmc Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
    Chandra R Tate
    Department of Medicine, Section of Hematology and Medical Oncology, Tulane University Health Sciences Center, 1430 Tulane Ave, New Orleans, LA 70112, USA
    Breast Cancer Res 14:R79. 2012
    ..Here, we investigate the ability of the histone deacetylase inhibitor panobinostat (LBH589) to selectively target triple-negative breast cancer (TNBC) cell proliferation and survival in vitro and tumorigenesis in vivo...
  9. pmc Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance
    James W Antoon
    Departments of Pharmacology, Tulane University School of Medicine, Tulane Avenue, New Orleans, LA, USA
    Sci Rep 2:539. 2012
    ..This first report identifying specific mechanisms underlying acquired resistance to TNF could lead to a better understanding of the progression of breast cancer in response to chemotherapy treatment...
  10. pmc Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells
    Quan Jiang
    Department of Chemistry, Xavier University of Louisiana, New Orleans, Louisiana 70125, USA
    J Med Chem 53:6153-63. 2010
    ..The most effective analogue, 2, was found to reduce in vivo estrogen stimulated MCF-7 cell tumorigenesis using a xenograft mouse model...
  11. ncbi request reprint Preferential star strand biogenesis of pre-miR-24-2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells
    Elizabeth C Martin
    Department of Medicine, Section of Hematology and Medical Oncology, Tulane University, New Orleans, Louisiaina
    Mol Carcinog 53:38-48. 2014
    ....
  12. pmc Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration
    Changhua Zhou
    Department of Chemistry, Xavier University of Louisiana, 1 Drexel Drive, New Orleans, LA 70125, USA
    Breast Cancer Res 14:R45. 2012
    ..This study was undertaken to investigate the global proteomic alterations in a tamoxifen resistant MCF-7 breast cancer cell line obtained by long term treatment of the wild type MCF-7 cell line with 4-hydroxytamoxifen (4-OH Tam)...
  13. pmc Phytoalexins, miRNAs and breast cancer: a review of phytochemical-mediated miRNA regulation in breast cancer
    Syreeta L Tilghman
    Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA
    J Health Care Poor Underserved 24:36-46. 2013
    ..This review will discuss how dietary intake of natural products, by regulating specific miRNAs, contribute to the prevention and treatment of breast cancer...
  14. pmc In vitro and in vivo evaluation of novel anticancer agents in triple negative breast cancer models
    KiTani Parker Johnson
    Division of Basic Pharmaceutical Sciences, Xavier University of Louisiana, School of Pharmacy, 1 Drexel Drive, New Orleans, LA 70125, USA
    J Health Care Poor Underserved 24:104-11. 2013
    ..DJ52 at 50 mg/kg caused significant decrease in tumor volume (p value <.05) by nearly 50% compared with the control with vehicle alone. These data suggest that DJ52 has merit for further evaluation as a novel anticancer agent...
  15. ncbi request reprint The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells
    Lyndsay V Rhodes
    Department of Medicine, Section of Hematology and Medical Oncology, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Oncol Rep 27:10-6. 2012
    ..This activity is correlated with TSA alteration of microRNA expression profiles indicative of a less aggressive phenotype...
  16. pmc Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640
    James W Antoon
    Department of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA
    Endocrinology 151:5124-35. 2010
    ....
  17. pmc Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer
    Lyndsay V Rhodes
    Department of Medicine, Section of Hematology and Medical Oncology, Center for Bioenvironmental Research, Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Cancer Res 71:603-13. 2011
    ..Our findings highlight CXCR4 signaling as a rational therapeutic target for the treatment of ER-positive, estrogen-independent breast carcinomas needing improved clinical management...
  18. doi request reprint Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence
    Lyndsay V Rhodes
    Department of Medicine, Section of Hematology and Medical Oncology, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Breast Cancer Res Treat 121:293-300. 2010
    ..This tumor stroma-cell interaction may provide a novel target for the treatment of estrogen receptor-positive, hormone-independent, and endocrine-resistant breast carcinoma...
  19. ncbi request reprint Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators
    Lyndsay V Rhodes
    Department of Medicine, Section of Hematology and Medical Oncology, Tulane University Health Sciences Center, 1430 Tulane Ave, New Orleans, LA, 70112, USA
    Breast Cancer Res Treat 145:593-604. 2014
    ..These data indicate therapeutic potential of LBH589 in targeting EMT and metastasis of TNBC...
  20. pmc Human uterine smooth muscle and leiomyoma cells differ in their rapid 17beta-estradiol signaling: implications for proliferation
    Erica N Nierth-Simpson
    Center for Bioenvironmental Research, Tulane University, New Orleans, Louisiana, USA
    Endocrinology 150:2436-45. 2009
    ..These studies demonstrate that rapid E2-signaling pathways contribute to the promotion of leiomyomas...